New drug duo aims to keep advanced nasopharyngeal cancer in check
NCT ID NCT07705243
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This Phase III trial tests whether adding an experimental drug called becotatug vedotin to standard anti-PD1 immunotherapy can better control advanced nasopharyngeal carcinoma that has spread or returned. About 86 adults whose cancer has stabilized after initial chemoimmunotherapy will receive either anti-PD1 alone or anti-PD1 plus becotatug vedotin for up to two years. Researchers will track how long the cancer stays under control and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of an experimental drug called becotatug vedotin and an anti-PD1 immunotherapy
- What this could lead to
- If successful, this combination could offer a more effective maintenance treatment to delay cancer progression in people with advanced nasopharyngeal carcinoma.
- What could go wrong
- This is a relatively small Phase III trial (86 participants), and the experimental drug may cause side effects or not improve outcomes over standard anti-PD1 alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a baking soda rinse tame radiation mouth sores?
- New surveillance strategy aims to catch residual cancer early in High-Risk nasopharyngeal carcinoma
- New combo strategy aims to catch and remove leftover cancer after radiation
- New combo injection targets Hard-to-Treat head and neck tumors
- New risk model may personalize Post-Chemo decisions for nasopharyngeal cancer
- New triple therapy aims to control advanced nose cancer